Towards a quality assurance for dosimetry in peptide receptor radionuclide therapy (PRRT) with 177Lu-DOTATATE

被引：0
|
作者：
Marin, G. [1 ]
Vanderlinden, B. [1 ]
Wimana, Z. [1 ]
Guiot, T. [1 ]
Karfis, I. [1 ]
Flamen, P. [1 ]
机构：
[1] Inst Jules Bordet, B-1000 Brussels, Belgium
来源：
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING | 2015年 / 42卷
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
OP386
引用
收藏
页码：S159 / S160
页数：2
相关论文
共 50 条
  • [41] Peptide receptor radionuclide therapy with 177Lu-DOTATATE: the IEO phase I-II study
    Bodei, Lisa
    Cremonesi, Marta
    Grana, Chiara M.
    Fazio, Nicola
    Iodice, Simona
    Baio, Silvia M.
    Bartolomei, Mirco
    Lombardo, Dario
    Ferrari, Mahila E.
    Sansovini, Maddalena
    Chinol, Marco
    Paganelli, Giovanni
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2011, 38 (12) : 2125 - 2135
  • [42] Radiation precautions for inpatient and outpatient 177Lu-DOTATATE peptide receptor radionuclide therapy of neuroendocrine tumours
    D. Levart
    E. Kalogianni
    B. Corcoran
    N. Mulholland
    G. Vivian
    EJNMMI Physics, 6
  • [43] Disturbing the redox balance as a new radiosensitizing strategy for Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE
    Delbart, W.
    Marin, G.
    Stamatopoulos, B.
    Ghanem, G. E.
    Flamen, P.
    Wimana, Z.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2022, 49 (SUPPL 1) : S59 - S59
  • [44] Treatment of inoperable or metastatic paragangliomas and pheochromocytomas with peptide receptor radionuclide therapy using 177Lu-DOTATATE
    Zandee, Wouter T.
    Feelders, Richard A.
    Duijzentkunstz, Daan A. Smit
    Hofland, Johannes
    Metselaar, R. Mick
    Oldenburg, Rogier A.
    van Linge, Anne
    Kam, Boen L. R.
    Teunissen, Jaap J. M.
    Korpershoek, Esther
    Hendriks, Johanna M.
    Abusaris, Huda
    Slagter, Cleo
    Franssen, Gaston J. H.
    Brabander, Tessa
    De Herder, Wouter W.
    EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2019, 181 (01) : 45 - 53
  • [45] 177Lu-Dotatate Peptide Receptor Radionuclide Therapy Dose Response in Small Intestinal Neuroendocrine Tumors
    Jahn, U. M. M.
    Ilan, E.
    Sandstrom, M.
    Bamerny, M.
    Garske-Roman, U.
    Lubberink, M.
    Sundin, A.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2017, 44 : S157 - S158
  • [46] Gallbladder Visualization in Peptide Receptor Radionuclide Therapy With 177Lu-DOTATATE A Potential Mimicker of Hepatic Metastases
    Diekmann, Johanna
    Werner, Rudolf A.
    Ross, Tobias L.
    Derlin, Thorsten
    CLINICAL NUCLEAR MEDICINE, 2020, 45 (12) : E521 - E522
  • [47] The efficacy of 177Lu-DOTATATE peptide receptor radionuclide therapy (PRRT) in patients with metastatic neuroendocrine tumours: a systematic review and meta-analysis
    Zhang, Jie
    Song, Qi
    Cai, Liang
    Xie, Ying
    Chen, Yue
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2020, 146 (06) : 1533 - 1543
  • [48] Radiation precautions for inpatient and outpatient 177Lu-DOTATATE peptide receptor radionuclide therapy of neuroendocrine tumours
    Levart, D.
    Kalogianni, E.
    Corcoran, B.
    Mulholland, N.
    Vivian, G.
    EJNMMI PHYSICS, 2019, 6 (1)
  • [49] Expanding the Indication for Novel Theranostic 177Lu-Dotatate Peptide Receptor Radionuclide Therapy: Proof-of-Concept of PRRT in Merkel Cell Cancer
    Kasi, Pashtoon M.
    Sharma, Akash
    Jain, Manoj K.
    CASE REPORTS IN ONCOLOGY, 2019, 12 (01): : 98 - 103
  • [50] 177Lu-DOTATATE Peptide Receptor Radionuclide Therapy: Dose Response in Small Intestinal Neuroendocrine Tumors
    Jahn, Ulrika
    Ilan, Ezgi
    Sandstrom, Mattias
    Garske-Roman, Ulrike
    Lubberink, Mark
    Sundin, Anders
    NEUROENDOCRINOLOGY, 2020, 110 (7-8) : 662 - 670
12345